Abivax shares up over 400% as ulcerative colitis drug scores two Phase 3 wins

Abivax soared on the Nasdaq Tuesday evening after the French biotech reported positive late-stage data from its inflammatory bowel disease drug candidate. The biotech’s miR-124 enhancer, dubbed obefazimod, met the primary endpoint of clinical remission ...